Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Charles Schwab Investment Management Inc. boosted its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 223.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 569,185 shares of the company's stock after acquiring an additional 393,202 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.91% of Fulcrum Therapeutics worth $2,032,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in shares of Fulcrum Therapeutics by 113.8% in the second quarter. SG Americas Securities LLC now owns 26,093 shares of the company's stock worth $162,000 after purchasing an additional 13,887 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at $3,084,000. Bank of New York Mellon Corp bought a new position in Fulcrum Therapeutics in the 2nd quarter worth $1,158,000. Rhumbline Advisers increased its stake in Fulcrum Therapeutics by 5,417.9% in the 2nd quarter. Rhumbline Advisers now owns 91,432 shares of the company's stock worth $567,000 after buying an additional 89,775 shares in the last quarter. Finally, National Bank of Canada FI raised its holdings in Fulcrum Therapeutics by 869.6% during the second quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock valued at $28,000 after acquiring an additional 4,000 shares during the period. Institutional investors own 89.83% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. HC Wainwright restated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Bank of America downgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and lowered their target price for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Leerink Partnrs cut shares of Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 12th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Finally, Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a "buy" rating to a "hold" rating and dropped their price objective for the company from $22.00 to $3.00 in a report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $9.33.

Fulcrum Therapeutics Stock Up 2.7 %

FULC traded up $0.12 on Tuesday, hitting $4.54. The company had a trading volume of 1,374,335 shares, compared to its average volume of 981,189. The business's fifty day simple moving average is $3.54 and its 200 day simple moving average is $5.87. Fulcrum Therapeutics, Inc. has a 12-month low of $2.86 and a 12-month high of $13.70. The company has a market cap of $244.88 million, a PE ratio of -14.65 and a beta of 2.14.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.